Viewing Study NCT06512246



Ignite Creation Date: 2024-10-26 @ 3:35 PM
Last Modification Date: 2024-10-26 @ 3:35 PM
Study NCT ID: NCT06512246
Status: COMPLETED
Last Update Posted: None
First Post: 2024-07-16

Brief Title: Failure Factors of ERCP After Gastrointestinal Reconstruction and Effectiveness Analysis of Remedial Measures
Sponsor: None
Organization: None

Study Overview

Official Title: Failure Factors of Endoscopic Retrograde Cholangiopancreatography After Gastrointestinal Reconstruction and Effectiveness of Remedial Measures
Status: COMPLETED
Status Verified Date: 2024-07
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: No
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: This is a retrospective study including 195 patients with gastrointestinal reconstruction who treated with Endoscopic Retrograde Cholangiopancreatography ERCP at Beijing friendship hospital The investigators assessed the outcomes of failure factors of ERCP and effectiveness of remedial measures
Detailed Description: Endoscopic retrograde cholangiopancreatography ERCP is an invasive procedure in which an endoscope is inserted into the descending part of the duodenum through the duodenal papilla and special instruments are used to enter the bile duct or pancreatic duct for examination and treatment with the assistance of X-ray

For normal upper digestive tract anatomy the technical success rate of ERCP was 976 and the treatment success rate was 952 But when the upper GI tract anatomy is altered due to surgery standard ERCP is operationally challenging and sometimes impossible For the treatment of gastroduodenal malignant tumors obesity and peptic ulcer subtotal gastrectomy and total gastrectomy are often used in combination with gastrointestinal reconstruction The most common gastrointestinal reconstruction procedures include Billroth I Billroth II Roux-en-Y and so on Billroth I is a gastroduodenal anastomosis which is more consistent with the original physiological condition of the gastrointestinal tract and usually does not increase the difficulty of ERCP operation Billroth II closed the duodenal end and anastomosed the stomach and jejunum to form an input loop and an output loop behind the gastrointestinal anastomosis Roux-en-Y is to close the duodenal end and transect the jejunum with Treitz ligament at a distance of 10-15cm The distal end is anastomosed with the remnant stomach and the proximal end is anastomosed with the jejunum at a distance of 45-60cm from the gastrointestinal anastomosis Due to the change of gastrointestinal structure after gastrointestinal reconstruction patients may be complicated with cholelithiasis pancreaticobile duct stenosis and other diseases requiring ERCP to assist in diagnosis and treatment However the alteration of digestive tract anatomical structure and possible postoperative complications including anastomotic fistula and anastomotic stenosis may lead to certain difficulty in ERCP operation The success of ERCP includes the success of ERCP implantation ERCP intubation and ERCP treatment According to previous studies at home and abroad the relevant success rates of ERCP after gastrointestinal reconstruction are 823-905 775-886 and 463-886 respectively Current studies suggest that the gastrointestinal remodeling procedure the type of operating endoscope and the experience of operating physicians are related to the success rate of ERCP operation When ERCP fails it can be treated with ERCP again percutaneous hepatic puncture biliary drainage PTCD endoscopic ultrasound and surgery

In a retrospective analysis 195 patients with gastrointestinal reconstruction who treated with Endoscopic Retrograde Cholangiopancreatography ERCP at Beijing Friendship Hospital were studied The investigators assessed the outcomes of failure factors of ERCP and effectiveness of remedial measures

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: None
Is a FDA Regulated Device?: None
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: None